Mineralocorticoid Receptor Inhibitors
4 drugsAbout Mineralocorticoid Receptor
The Mineralocorticoid Receptor (MR) is a ligand-activated transcription factor that regulates sodium and potassium balance, blood volume, and blood pressure. Primarily known for kidney function, it is also expressed in the heart and brain, influencing various physiological processes.
The broad expression profile of MR makes it a compelling drug target, particularly in the cardiovascular therapeutic area. Currently, there is no genetic evidence available linking the Mineralocorticoid Receptor to specific diseases.
Two FDA-approved drugs target MR: Eplerenone and Kerendia. Both are small molecules, with Novartis and Bayer marketing these drugs across cardiovascular and other therapeutic areas.
Top Mineralocorticoid Receptor Drugs
Novartis and Bayer are the only companies with approved drugs targeting the Mineralocorticoid Receptor.
Limited competition suggests a high barrier to entry, but also an opportunity for new players with differentiated therapies.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| CAROSPIR | CMP DEV LLC | 2017 | 3 |
Mineralocorticoid Receptor Drug Modality Landscape
Modalities
Routes of Administration
Mineralocorticoid Receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide differentiation in a small molecule-heavy field.
Mineralocorticoid Receptor Clinical Trials 240 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Mineralocorticoid Receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 37 | 27 | 6 | 4 | 82% |
| Phase 2 | 74 | 39 | 12 | 22 | 76% |
| Phase 3 | 50 | 27 | 3 | 20 | 90% |
| Phase 4 | 79 | 33 | 18 | 28 | 65% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Mineralocorticoid Receptor Drug Approval Timeline (1960 - 2021)
The first drug was approved in 2008 (Eplerenone), with the most recent approval in 2021 (Kerendia), spanning 14 years.
Relatively slow approval rate indicates potential challenges in drug development or a saturated market for existing approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 4 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 161 (21 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Mineralocorticoid Receptor. A trial counts if an approved drug acting on Mineralocorticoid Receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.